pre-update Archives

Publication

Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy

Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. The objective…

CertaraAugust 15, 2013

Press Release

Certara Enhances SYBYL-X Drug Design and Discovery Software Suite

SYBYL-X 2.1 offers improved job control and increased QSAR accessibility ST. LOUIS, MO – Aug.…

CertaraAugust 6, 2013

Publication

A Pilot Study Assessing the Bioavailability and Pharmacokinetics of Diazepam After Intranasal and Intravenous Administration in Healthy Volunteers

Diazepam rectal gel (Diastat®) is the only FDA-approved product indicated for acute repetitive seizures. Despite…

CertaraAugust 1, 2013

Publication

Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies

CertaraAugust 1, 2013

Publication

Basic Concepts in Physiologically-based Pharmacokinetic Modeling in Drug Discovery and Development

The aim of this tutorial is to introduce the concept of physiologically based pharmacokinetic (PBPK)…

CertaraAugust 1, 2013

Press Release

Pfizer Deploys Certara’s D360 for Scientific Data Access and Analysis

Bio-IT World News Bulletin describes how Pfizer has adopted D360 as Pfizer’s core research platform. …

CertaraJuly 29, 2013

Publication

Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis

Clinical trial simulation (CTS) and model-based meta-analysis (MBMA) can increase our understanding of small, first-in-patient…

CertaraJuly 24, 2013

Publication

A Mechanistic Framework for In Vitro-In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug-drug Interaction Between Rosuvastatin and Cyclosporine

The interplay between liver metabolizing enzymes and transporters is a complex process involving system-related parameters such as liver blood perfusion…

CertaraJuly 24, 2013

Publication

A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

CertaraJuly 20, 2013

Publication

Model-based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

The pharmaceutical industry continues to face significant challenges. Very few compounds that enter development reach…

CertaraJuly 1, 2013

pre-update

Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy

Certara Enhances SYBYL-X Drug Design and Discovery Software Suite

A Pilot Study Assessing the Bioavailability and Pharmacokinetics of Diazepam After Intranasal and Intravenous Administration in Healthy Volunteers

Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies

Basic Concepts in Physiologically-based Pharmacokinetic Modeling in Drug Discovery and Development

Pfizer Deploys Certara’s D360 for Scientific Data Access and Analysis

Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis

A Mechanistic Framework for In Vitro-In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug-drug Interaction Between Rosuvastatin and Cyclosporine

A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

Model-based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Newsletter sign up

Quick links

Solutions

Contact